Vistara

Most comprehensive prenatal single-gene screening test. Conditions screened by Vistara have a combined incidence of 1 in 600 - higher than that of Downs syndrome.

Vistara is a complement to Panorama test and a strong extension of the Panorama NIPT.


Download Vistara Patient Brochure Here

 

What is Vistara?

 

The Vistara prenatal screen is a DNA screening test that provides with the probability that a baby has certain genetic conditions that include one or more of the following:

  • cognitive disability
  • requires surgical or medical intervention
  • affect quality of life

 

Vistara looks for small DNA changes, or single-gene mutations, that could affect a baby’s health. Like other non-invasive prenatal tests (NIPTs), Vistara analyzes DNA from the placenta that is found in a mother’s blood.

Vistara can be performed as early as nine weeks into pregnancy and poses no risk of miscarriage to the baby. Vistara requires samples from both biological parents.

 

What Vistara screens for

Vistara screens for autosomal or X-linked dominant mutations across 30 genes, such as Noonan syndrome, osteogenesis imperfecta, and Rett syndrome. The conditions screened by Vistara are commonly caused by de novo mutations – single-gene mutations in cell-free fetal (placental) DNA – and usually not inherited or tied to patient or family history.

 

Prenatal testing for these conditions can lead to improved delivery management, targeted

neonatal care, and more comprehensive prenatal education for parents

 

Vistara screens for a set of disorders that, combined, occur more frequently than Down syndrome2,3. These conditions are not covered by traditional NIPTs or carrier screening.

 

Download Vistara conditions list here

 

How is Vistara different from other NIPTs?

Vistara screens for serious conditions across 30 genes that are not screened for by standard NIPTs. Other NIPTs screen for chromosomal abnormalities, such as Down syndrome, rather than looking for small changes, or single-gene mutations, in DNA from the placenta.

Vistara does not test for chromosomal abnormalities such as extra chromosomes (e.g. Down syndrome), or test for the baby’s gender. However, results from standard NIPT and Vistara together can help reduce the chance for a wider range of genetic abnormalities.

 

How does information about genetic abnormalities affect the pregnancy care plan?

Information from genetic screening helps parents to make the best decisions for their families.

Many conditions screened by Vistara may require specialized medical care prenatally, at birth, and into childhood. Knowing about genetic conditions sooner can empower patients to learn about options to care for an affected child.

 

Vistara results

Results from Vistara will show whether a disease-causing or likely disease-causing single-gene mutation has been identified. Results will provide valuable information to help patients and doctors plan prenatal care and delivery. Like other screening tests, Vistara is not a diagnostic test and does not provide a definitive diagnosis of any conditions screened.

 

Amniocentesis or CVS can be performed before birth, or the baby can be tested with a blood sample at or after delivery.
 

Consider Vistara for the following indications

  • Advanced paternal age (older than 40 years)
  • Women who want to know 'everything' or as an adjunct tol CVS or amniocentesis
  • Ultrasound anomalies, such as shortened long bones an increased nuchal translucency
References:
1. Validation data, Baylor. 2016.
2. Gene Reviews. https://www.ncbi.nlm.nih.gov/books/NBK1116/
3. Genetics Home Reference. https://ghr.nlm.nih.gov/
4. Meyers A et al. “Perinatal features of the RASopathies: Noonan syndrome, cardiofaciocutaneous syndrome and Costello syndrome.” Am J Med Genet A. 2014;164A:2814-21.
5. Yimgang DP et al. “Health outcomes of neonates with osteogenesis imperfecta: a cross-sectional study.” J Matern Fetal Neonatal Med. 2016 Dec;29(23):3889-93.
CAP accredited, ISO 13485, and CLIA certified. © 2019 Natera, Inc. All Rights Reserved.